Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Pinez K, (2016) Leukemia (Link to Abstract)


Currently most clinical trials of CAR T-cells are against B-cell malignancies. There are not many studies about CAR T-cells against T-cell malignancies. In this paper, the authors described a CD4 antigen targeted CAR T-cell, derived from CD8+ T cells.  They demonstrated the in vitro efficacy against CD4+lymphoma, leukemia cell lines and mouse models.


* CD4 CAR T cells present a new approach for the treatment of CD4+ T-cell malignancies. Although CD4 T-cell depletion leads to susceptibility of infection (as in HI


* patients), this may potentially be used as a bridging therapy for bone marrow transplant.